Williams et al., 1996 - Google Patents
Correlation between expression of antibodies to histone H2B and clinical activity in HIV‐infected individualsWilliams et al., 1996
View PDF- Document ID
- 7766096825551521341
- Author
- Williams W
- Whalley A
- Comacchio R
- Rosenberg J
- Watts R
- Isenberg D
- Mc Cutchan J
- Morrow W
- Publication year
- Publication venue
- Clinical & Experimental Immunology
External Links
Snippet
Levels of autoantibodies specific for the histone, H2B, were measured in individuals with HIV infection. In comparison with normal (uninfected) controls, infected patients, particularly those with symptomatic disease, had significantly elevated titres of anti‐H2B antibodies …
- 102000004965 antibodies 0 title abstract description 67
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—AIDS or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bettaieb et al. | Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura | |
| Silvestris et al. | Autoreactivity in HIV-1 infection: the role of molecular mimicry | |
| Bowness et al. | Hereditary C1q deficiency and systemic lupus erythematosus | |
| Clerici et al. | Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro | |
| Neurath et al. | Bovine β–lactoglobulin modified by 3–hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV | |
| Fiorino et al. | Paraproteinemia, plasmacytoma, myeloma and HIV infection | |
| Lopalco et al. | Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity | |
| Buskila et al. | Musculoskeletal manifestations of infection with human immunodeficiency virus | |
| Nabi et al. | Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy | |
| AU690694B2 (en) | Methods for the identification of compounds capable of abrogating HIV-1 VPR-RIP-1 binding interactions | |
| WO1992008983A1 (en) | Hiv marker/aids vaccine | |
| Grant et al. | Distribution of antibodies against denatured collagen in AIDS risk groups and homosexual AIDS patients suggests a link between autoimmunity and the immunopathogenesis of AIDS. | |
| KOZLOWSKI et al. | Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins | |
| Williams et al. | Correlation between expression of antibodies to histone H2B and clinical activity in HIV‐infected individuals | |
| Müller et al. | Relationship of antibodies against CD4+ T cells in HIV-infected patients to markers of activation and progression: autoantibodies are closely associated with CD4 cell depletion | |
| Burastero et al. | Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals | |
| Neurath et al. | Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV‐1) envelope glycoprotein gp120 | |
| Klasse et al. | Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG | |
| WO1995032311A1 (en) | Non-hiv antibodies as disease markers | |
| Corbeau et al. | An early postinfection signal mediated by monoclonal anti-beta 2 microglobulin antibody is responsible for delayed production of human immunodeficiency virus type 1 in peripheral blood mononuclear cells | |
| Faghiri et al. | Antibodies to cardiolipin and β2-glycoprotein-1 in HTLV-1-associated myelopathy/tropical spastic paraparesis | |
| Süsal et al. | Anti-IgG autoantibodies in HIV-infected hemophilia patients | |
| Giordanengo et al. | Autoantibodies directed against CD43 molecules with an altered glycosylation status on human immunodeficiency virus type 1 (HIV-1)-infected CEM cells are found in all HIV-1+ individuals | |
| Morrow et al. | Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses | |
| Zaitseva et al. | Antibodies to MHC class II peptides are present in HIV‐1‐positive sera |